Reviva Pharmaceuticals Holdings, INC Schedule 13G passive stakes

Barclays PLC has filed a Schedule 13G, disclosing a minimal beneficial ownership of 20 shares in Reviva Pharmaceuticals, representing 0.00% of the class.

Integrated Core Strategies, Millennium Management, and Israel A. Englander have jointly reported beneficial ownership of 8.2% of Reviva Pharmaceuticals Holdings, Inc. common stock.

UBS Group AG has filed a Schedule 13G, reporting no beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock as of June 30, 2026.

CVI Investments and Heights Capital Management report a combined 4.9% stake in Reviva Pharmaceuticals Holdings, Inc., primarily through warrants.

Barclays PLC has filed a Schedule 13G reporting a 5.96% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc.

UBS Group AG has reported beneficial ownership of 746,095 shares, representing 5.8% of the outstanding common stock of Reviva Pharmaceuticals Holdings, Inc., as of March 31, 2026.

Millennium Management LLC and its affiliates have reported a 6.2% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc.

CVI Investments, managed by Heights Capital Management, has reported a 5.2% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc.

Millennium Management and affiliated entities report a 2.8% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2025.

683 Capital Management, LP, and Ari Zweiman have reported a 5.36% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc., primarily through common stock and exercisable warrants.

Tang Capital Management and affiliates reported a 4.8% passive ownership stake in Reviva Pharmaceuticals Holdings, Inc., primarily through exercisable warrants.

Highbridge Capital Management, LLC has disclosed a 9.9% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. through warrants, subject to a 9.9% ownership blocker.

CVI Investments, managed by Heights Capital Management, Inc., has reported a 4.9% passive beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. through warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 5.9% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc., totaling 4,000,000 shares.

Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have disclosed a combined beneficial ownership of 7.80% in Reviva Pharmaceuticals Holdings, Inc., totaling 3,910,304 shares, including those exercisable via warrants.

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting a 2.82% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2024.

CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.9% in Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2024.